Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.21% |
| 2 | Technology | 12.9% |
| 3 | Consumer Discretionary | 10.45% |
| 4 | Financials | 8.47% |
| 5 | Industrials | 7.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2551
Inovio Pharmaceuticals
INO
$55.7M
| $1.19M | ﹤0.01% |
29,958
+18,716
| +166% | +$563K |
|
|
SRRA
2552
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $1.18M | ﹤0.01% |
86,412
+20,618
| +31% | +$269K |
|
2553
Baytex Energy
BTE
$3.25B
| $1.18M | ﹤0.01% |
811,949
+151,652
| +23% | +$187K |
|
2554
Viemed Healthcare
VMD
$447M
| $1.17M | ﹤0.01% |
187,400
+174,300
| +1,331% | +$1.21M |
|
|
FRAN
2555
DELISTED
Francesca's Holdings Corporation
FRAN
| $1.17M | ﹤0.01% |
113,138
+8,200
| +8% | +$124K |
|
2556
Oramed Pharmaceuticals
ORMP
$167M
| $1.17M | ﹤0.01% |
227,725
+15,800
| +7% | +$59.2K |
|
2557
Nelnet
NNI
$4.88B
| $1.17M | ﹤0.01% |
20,100
-53,831
| -73% | -$3.3M |
|
2558
State Street SPDR Portfolio S&P 500 Growth ETF
SPYG
$51.7B
| $1.17M | ﹤0.01% |
+27,800
| New | +$1.11M |
|
|
GFED
2559
DELISTED
Guaranty Federal Bancshares In
GFED
| $1.16M | ﹤0.01% |
46,029
+7,328
| +19% | +$181K |
|
|
ATHX
2560
DELISTED
Athersys, Inc. Common Stock
ATHX
| $1.16M | ﹤0.01% |
37,650
-2,627
| -7% | -$86.1K |
|
|
GRCE
2561
Grace Therapeutics
GRCE
$33.8M
| $1.15M | ﹤0.01% |
9,806
+4,575
| +87% | +$452K |
|
|
BNFT
2562
DELISTED
Benefitfocus, Inc.
BNFT
| $1.15M | ﹤0.01% |
+52,545
| New | +$1.19M |
|
|
SCHV
2563
Schwab US Large-Cap Value ETF
SCHV
$15.7B
| $1.15M | ﹤0.01% |
57,300
+16,800
| +41% | +$326K |
|
|
ZEUS
2564
DELISTED
Olympic Steel
ZEUS
| $1.15M | ﹤0.01% |
+64,000
| New | +$1.02M |
|
|
INVX
2565
Innovex International
INVX
$1.96B
| $1.15M | ﹤0.01% |
24,400
-79,500
| -77% | -$3.64M |
|
2566
Fidelity Total Bond ETF
FBND
$26.9B
| $1.14M | ﹤0.01% |
+22,100
| New | +$1.14M |
|
2567
Atlanticus Holdings
ATLC
$1.59B
| $1.14M | ﹤0.01% |
126,708
+42,107
| +50% | +$333K |
|
2568
Fulgent Genetics
FLGT
$470M
| $1.14M | ﹤0.01% |
88,421
-82,059
| -48% | -$975K |
|
|
FPAY
2569
DELISTED
FlexShopper
FPAY
| $1.14M | ﹤0.01% |
450,595
+168,593
| +60% | +$292K |
|
|
TCDA
2570
DELISTED
Tricida, Inc. Common Stock
TCDA
| $1.14M | ﹤0.01% |
+30,200
| New | +$1.13M |
|
|
RRD
2571
DELISTED
RR Donnelley & Sons Co.
RRD
| $1.14M | ﹤0.01% |
288,566
+220,473
| +324% | +$871K |
|
2572
Acushnet Holdings
GOLF
$5.93B
| $1.13M | ﹤0.01% |
34,700
+23,500
| +210% | +$698K |
|
2573
Fuel Tech
FTEK
$43.9M
| $1.13M | ﹤0.01% |
1,186,238
+52,987
| +5% | +$51K |
|
2574
iShares MSCI Japan ETF
EWJ
$21.9B
| $1.13M | ﹤0.01% |
+19,000
| New | +$1.12M |
|
|
OPOF
2575
DELISTED
Old Point Financial
OPOF
| $1.13M | ﹤0.01% |
40,935
+2,300
| +6% | +$61.6K |
|
Similar funds
Renaissance Technologies's Q4 2019 Portfolio in Review
As of Q4 2019, Renaissance Technologies held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Renaissance Technologies's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Renaissance Technologies's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Renaissance Technologies added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Renaissance Technologies's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Renaissance Technologies fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Renaissance Technologies's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Renaissance Technologies opened 518 new positions and closed 443 in Q4 2019.
- Renaissance Technologies's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.